<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36831611</PMID><DateRevised><Year>2023</Year><Month>02</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2072-6694</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>16</Day></PubDate></JournalIssue><Title>Cancers</Title><ISOAbbreviation>Cancers (Basel)</ISOAbbreviation></Journal><ArticleTitle>Long-COVID in Patients with Cancer Previously Treated with Early Anti-SARS-CoV-2 Therapies in an Out-of-Hospital Setting: A Single-Center Experience.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1269</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/cancers15041269</ELocationID><Abstract><AbstractText>The incidence of long COVID in a cohort of patients with cancer with or without previous treatment with early therapies anti-SARS-CoV-2 in an out-of-hospital setting have to be elucidated. We prospectively enrolled all patients treated for a solid tumor at the department of Medical Oncology of the Fondazione IRCCS Policlinico San Matteo with a positive SARS-CoV-2 antigen or polymerase chain reaction test from January to September 2022 (Omicron surge). Ninety-seven patients answered the survey questions by telephone at least 12 weeks after COVID-19 diagnosis in order to evaluate the incidence of long COVID symptoms. Only twelve patients (12.4%) reported long COVID. No significant difference between early therapies anti-SARS-CoV-2 31 and long COVID (<i>p</i> = 0.443) was seen. The female sex (<i>p</i> = 0.024) and diabetes mellitus (<i>p</i> = 0.014) are significantly associated with long COVID. No statistically significant difference between the two groups (Long COVID vs. No Long COVID) according to the time to nasal swab viral clearance (<i>p</i> = 0.078). The overlap between the symptoms related to the oncological disease/oncological treatment and the symptoms of long COVID is one of the main future challenges that oncologists will have to manage.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lasagna</LastName><ForeName>Angioletta</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-9611-1164</Identifier><AffiliationInfo><Affiliation>Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albi</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Electrical, Computer and Biomedical Engineering, University of Pavia, 27100 Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Figini</LastName><ForeName>Simone</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basile</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sacchi</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases I, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bruno</LastName><ForeName>Raffaele</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases I, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Surgical Diagnostic and Pediatric Sciences, University of Pavia, 27100 Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pedrazzoli</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-9419-7160</Identifier><AffiliationInfo><Affiliation>Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine and Medical Therapy, University of Pavia, 27100 Pavia, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>grant no 08067620</GrantID><Agency>Policlinico San Matteo Fondazione</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cancers (Basel)</MedlineTA><NlmUniqueID>101526829</NlmUniqueID><ISSNLinking>2072-6694</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">brain fog</Keyword><Keyword MajorTopicYN="N">cancer</Keyword><Keyword MajorTopicYN="N">long-COVID</Keyword><Keyword MajorTopicYN="N">nirmatrelvir/ritonavir</Keyword><Keyword MajorTopicYN="N">outcome</Keyword><Keyword MajorTopicYN="N">real-life data</Keyword><Keyword MajorTopicYN="N">remdesivir</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>2</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>25</Day><Hour>1</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>2</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36831611</ArticleId><ArticleId IdType="pmc">PMC9953958</ArticleId><ArticleId IdType="doi">10.3390/cancers15041269</ArticleId><ArticleId IdType="pii">cancers15041269</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhu N., Zhang D., Wang W., Li X., Yang B., Song J., Zhao X., Huang B., Shi W., Lu R., et al. China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N. Engl. J. Med. 2020;382:727&#x2013;733. doi: 10.1056/NEJMoa2001017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2001017</ArticleId><ArticleId IdType="pmc">PMC7092803</ArticleId><ArticleId IdType="pubmed">31978945</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H., Han H., He T., Labbe K.E., Hernandez A.V., Chen H., Velcheti V., Stebbing J., Wong K.K. Clinical Characteristics and Outcomes of COVID-19&#x2013;Infected Cancer Patients: A Systematic Review and Meta-Analysis. J. Natl. Cancer Inst. 2021;113:371&#x2013;380. doi: 10.1093/jnci/djaa168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnci/djaa168</ArticleId><ArticleId IdType="pmc">PMC7665647</ArticleId><ArticleId IdType="pubmed">33136163</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehmsen S., Asmussen A., Jeppesen S.S., Nilsson A.C., &#xd8;sterlev S., Kragh A., Frederiksen H., Ditzel H.J. Antibody responses following third mRNA COVID-19 vaccination in patients with cancer and potential timing of a fourth vaccination. Cancer Cell. 2022;40:338&#x2013;339. doi: 10.1016/j.ccell.2022.02.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2022.02.011</ArticleId><ArticleId IdType="pmc">PMC8867110</ArticleId><ArticleId IdType="pubmed">35216675</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasagna A., Bergami F., Lilleri D., Percivalle E., Quaccini M., Serra F., Comolli G., Sarasini A., Sammartino J.C., Ferrari A., et al. Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: A longitudinal cohort study with a focus on the variants of concern. ESMO Open. 2022;7:100574. doi: 10.1016/j.esmoop.2022.100574.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.esmoop.2022.100574</ArticleId><ArticleId IdType="pmc">PMC9353611</ArticleId><ArticleId IdType="pubmed">36029652</ArticleId></ArticleIdList></Reference><Reference><Citation>Gopinath S., Ishak A., Dhawan N., Poudel S., Shrestha P.S., Singh P., Xie E., Tahir P., Marzaban S., Michel J., et al. Characteristics of COVID-19 breakthrough infections among vaccinated individuals and associated risk factors: A systematic review. Trop. Med. Infect. Dis. 2022;7:81. doi: 10.3390/tropicalmed7050081.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/tropicalmed7050081</ArticleId><ArticleId IdType="pmc">PMC9144541</ArticleId><ArticleId IdType="pubmed">35622708</ArticleId></ArticleIdList></Reference><Reference><Citation>AIFA: Registri Farmaci Sottoposti a Monitoraggio.  [(accessed on 15 January 2023)]; Available online:  https://www.aifa.gov.it/web/guest/emergenza-covid-19.</Citation></Reference><Reference><Citation>Lasagna A., Cassaniti I., Lilleri D., Quaccini M., Ferrari A., Sacchi P., Bruno R., Baldanti F., Pedrazzoli P. Effectiveness of the available early therapies in reducing severe COVID-19 in non-hospitalized patients with solid tumors on active treatment. Front. Med. 2022;9:1036473. doi: 10.3389/fmed.2022.1036473.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.1036473</ArticleId><ArticleId IdType="pmc">PMC9643502</ArticleId><ArticleId IdType="pubmed">36388947</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  . A Clinical Case Definition of Post COVID-19 Condition by a Delphi Consensus. WHO; Geneva, Switzerland: 2021.  [(accessed on 18 December 2022)].  Available online:  https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1.</Citation></Reference><Reference><Citation>Brightling C.E., Evans R.A. Long COVID: Which symptoms can be attributed to SARS-CoV-2 infection? Lancet. 2022;400:411&#x2013;413. doi: 10.1016/S0140-6736(22)01385-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01385-X</ArticleId><ArticleId IdType="pmc">PMC9352303</ArticleId><ArticleId IdType="pubmed">35933996</ArticleId></ArticleIdList></Reference><Reference><Citation>Chasco E.E., Dukes K., Jones D., Comellas A.P., Hoffman R.M., Garg A. Brain Fog and Fatigue following COVID-19 Infection: An Exploratory Study of Patient Experiences of Long COVID. Int. J. Environ. Res. Public Health. 2022;19:15499. doi: 10.3390/ijerph192315499.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph192315499</ArticleId><ArticleId IdType="pmc">PMC9737348</ArticleId><ArticleId IdType="pubmed">36497573</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M., Dercon Q., Luciano S., Geddes J.R., Husain M., Harrison P.J. Incidence, Co-Occurrence, and Evolution of Long-COVID Features: A 6-Month Retrospective Cohort Study of 273,618 Survivors of COVID-19. PLoS Med. 2021;18:e1003773. doi: 10.1371/journal.pmed.1003773.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003773</ArticleId><ArticleId IdType="pmc">PMC8478214</ArticleId><ArticleId IdType="pubmed">34582441</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortellini A., Salazar R., Gennari A., Aguilar-Company J., Bower M., Bertuzzi A., Brunet J., Lambertini M., Maluquer C., Pedrazzoli P., et al. Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry. Eur. J. Cancer. 2022;170:10&#x2013;16. doi: 10.1016/j.ejca.2022.03.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejca.2022.03.019</ArticleId><ArticleId IdType="pmc">PMC9040509</ArticleId><ArticleId IdType="pubmed">35576848</ArticleId></ArticleIdList></Reference><Reference><Citation>Monroy-Iglesias M.J., Tremble K., Russell B., Moss C., Dolly S., Sita-Lumsden A., Cortellini A., Pinato D.J., Rigg A., Karagiannis S.N., et al. Long-term effects of COVID-19 on cancer patients: The experience from Guy&#x2019;s Cancer Centre. Future Oncol. 2022 doi: 10.2217/fon-2022-0088. Online ahead of print .</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fon-2022-0088</ArticleId><ArticleId IdType="pubmed">36172860</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapti V., Tsaganos T., Vathiotis I.A., Syrigos N.K., Li P., Poulakou G. New Insights into SARS-CoV-2 and Cancer Cross-Talk: Does a Novel Oncogenesis Driver Emerge? Vaccines. 2022;10:1607. doi: 10.3390/vaccines10101607.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10101607</ArticleId><ArticleId IdType="pmc">PMC9611551</ArticleId><ArticleId IdType="pubmed">36298472</ArticleId></ArticleIdList></Reference><Reference><Citation>Queiroz M.A.F., Neves P., Lima S.S., Lopes J.D.C., Torres M., Vallinoto I., Bichara C.D.A., Dos Santos E.F., de Brito M.T.F.M., da Silva A.L.S., et al. Cytokine Profiles Associated With Acute COVID-19 and Long COVID-19 Syndrome. Front. Cell Infect. Microbiol. 2022;12:922422. doi: 10.3389/fcimb.2022.922422.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2022.922422</ArticleId><ArticleId IdType="pmc">PMC9279918</ArticleId><ArticleId IdType="pubmed">35846757</ArticleId></ArticleIdList></Reference><Reference><Citation>Pusztai L., Mendoza T.R., Reuben J.M., Martinez M.M., Willey J.S., Lara J., Syed A., Fritsche H.A., Bruera E., Booser D., et al. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine. 2004;25:94&#x2013;102. doi: 10.1016/j.cyto.2003.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2003.10.004</ArticleId><ArticleId IdType="pubmed">14698135</ArticleId></ArticleIdList></Reference><Reference><Citation>Piotrowski I., Kulcenty K., Suchorska W. Interplay between inflammation and cancer. Rep. Pract. Oncol. Radiother. 2020;25:422&#x2013;427. doi: 10.1016/j.rpor.2020.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rpor.2020.04.004</ArticleId><ArticleId IdType="pmc">PMC7191124</ArticleId><ArticleId IdType="pubmed">32372882</ArticleId></ArticleIdList></Reference><Reference><Citation>Rusin A., Seymour C., Cocchetto A., Mothersill C. Commonalities in the Features of Cancer and Chronic Fatigue Syndrome (CFS): Evidence for Stress-Induced Phenotype Instability? Int. J. Mol. Sci. 2022;23:691. doi: 10.3390/ijms23020691.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23020691</ArticleId><ArticleId IdType="pmc">PMC8775947</ArticleId><ArticleId IdType="pubmed">35054876</ArticleId></ArticleIdList></Reference><Reference><Citation>Boglione L., Meli G., Poletti F., Rostagno R., Moglia R., Cantone M., Esposito M., Scianguetta C., Domenicale B., Di Pasquale F., et al. Risk factors and incidence of long-COVID syndrome in hospitalized patients: Does remdesivir have a protective effect? QJM. 2022;114:865&#x2013;871. doi: 10.1093/qjmed/hcab297.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/qjmed/hcab297</ArticleId><ArticleId IdType="pmc">PMC8690187</ArticleId><ArticleId IdType="pubmed">34850210</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong W., Jiang X., Yang X., Feng T., Duan Z., Wang W., Sun Z., Chen L., Nie X., Zhu C., et al. The efficacy of paxlovid in elderly patients infected with SARS-CoV-2 omicron variants: Results of a non-randomized clinical trial. Front. Med. 2022;9:980002. doi: 10.3389/fmed.2022.980002.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.980002</ArticleId><ArticleId IdType="pmc">PMC9485497</ArticleId><ArticleId IdType="pubmed">36148451</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D., Bosworth M.L., King S., Pouwels K.B., Glickman M., Nafilyan V., Zaccardi F., Khunti K., Alwan N.A., Walker A.S. Risk of Long COVID in People Infected with Severe Acute Respiratory Syndrome Coronavirus 2 After 2 Doses of a Coronavirus Disease 2019 Vaccine: Community-Based, Matched Cohort Study. Open Forum Infect. Dis. 2022;9:ofac464. doi: 10.1093/ofid/ofac464.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofac464</ArticleId><ArticleId IdType="pmc">PMC9494414</ArticleId><ArticleId IdType="pubmed">36168555</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-Las-Pe&#xf1;as C., Ortega-Santiago R., Fuensalida-Novo S., Mart&#xed;n-Guerrero J.D., Pellicer-Valero O.J., Torres-Macho J. Differences in Long-COVID Symptoms between Vaccinated and Non-Vaccinated (BNT162b2 Vaccine) Hospitalized COVID-19 Survivors Infected with the Delta Variant. Vaccines. 2022;10:1481. doi: 10.3390/vaccines10091481.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10091481</ArticleId><ArticleId IdType="pmc">PMC9504977</ArticleId><ArticleId IdType="pubmed">36146560</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-las-Pe&#xf1;as C., Mart&#xed;n-Guerrero J.D., Pellicer-Valero &#xd3;.J., Navarro-Pardo E., G&#xf3;mez-Mayordomo V., Cuadrado M.L., Arias-Naval&#xf3;n J.A., Cigar&#xe1;n-M&#xe9;ndez M., Hern&#xe1;ndez-Barrera V., Arendt-Nielsen L. Female Sex Is a Risk Factor Associated with Long-Term Post-COVID Related-Symptoms but Not with COVID-19 Symptoms: The LONG-COVID-EXP-CM Multicenter Study. J. Clin. Med. 2022;11:413. doi: 10.3390/jcm11020413.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11020413</ArticleId><ArticleId IdType="pmc">PMC8778106</ArticleId><ArticleId IdType="pubmed">35054108</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend L., Dyer A.H., Jones K., Dunne J., Mooney A., Gaffney F., O&#x2019;Connor L., Leavy D., O&#x2019;Brien K., Dowds J., et al. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLoS ONE. 2020;15:e0240784. doi: 10.1371/journal.pone.0240784.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0240784</ArticleId><ArticleId IdType="pmc">PMC7652254</ArticleId><ArticleId IdType="pubmed">33166287</ArticleId></ArticleIdList></Reference><Reference><Citation>Scully E.P., Schumock G., Fu M., Massaccesi G., Muschelli J., Betz J., Klein E.Y., West N.E., Robinson M., Garibaldi B.T., et al. Sex and Gender Differences in Testing, Hospital Admission, Clinical Presentation, and Drivers of Severe Outcomes From COVID-19. Open Forum Infect Dis. 2021;8:ofab448. doi: 10.1093/ofid/ofab448.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofab448</ArticleId><ArticleId IdType="pmc">PMC8465334</ArticleId><ArticleId IdType="pubmed">34584899</ArticleId></ArticleIdList></Reference><Reference><Citation>Fortunato F., Martinelli D., Lo Caputo S., Santantonio T., Dattoli V., Lopalco P.L., Prato R. Sex and gender differences in COVID-19: An Italian local register-based study. BMJ Open. 2021;11:e051506. doi: 10.1136/bmjopen-2021-051506.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2021-051506</ArticleId><ArticleId IdType="pmc">PMC8507404</ArticleId><ArticleId IdType="pubmed">34620662</ArticleId></ArticleIdList></Reference><Reference><Citation>Kloc M., Ghobrial R.M., Kubiak J.Z. The Role of Genetic Sex and Mitochondria in Response to COVID-19 Infection. Int. Arch. Allergy Immunol. 2020;181:629&#x2013;634. doi: 10.1159/000508560.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000508560</ArticleId><ArticleId IdType="pmc">PMC7360490</ArticleId><ArticleId IdType="pubmed">32564017</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakravarty D., Nair S.S., Hammouda N., Ratnani P., Gharib Y., Wagaskar V., Mohamed N., Lundon D., Dovey Z., Kyprianou N., et al. Sex differences in SARS-CoV-2 infection rates and the potential link to prostate cancer. Commun. Biol. 2020;3:374. doi: 10.1038/s42003-020-1088-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-020-1088-9</ArticleId><ArticleId IdType="pmc">PMC7343823</ArticleId><ArticleId IdType="pubmed">32641750</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasagna A., Zuccaro V., Ferraris E., Corbella M., Bruno R., Pedrazzoli P. COVID-19 and breast cancer: May the microbiome be the issue? Future Oncol. 2021;17:123&#x2013;126. doi: 10.2217/fon-2020-0764.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fon-2020-0764</ArticleId><ArticleId IdType="pmc">PMC7720649</ArticleId><ArticleId IdType="pubmed">33244989</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q., Mak J.W.Y., Su Q., Yeoh Y.K., Lui G.C., Ng S.S.S., Zhang F., Li A.Y.L., Lu W., Hui D.S., et al. Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome. Gut. 2022;71:544&#x2013;552. doi: 10.1136/gutjnl-2021-325989.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-325989</ArticleId><ArticleId IdType="pubmed">35082169</ArticleId></ArticleIdList></Reference><Reference><Citation>Raveendran A.V., Misra A. Post COVID-19 syndrome (&#x201c;Long COVID&#x201d;) and diabetes: Challenges in diagnosis and management. Diabetes Metab. Syndr. 2021;15:102235. doi: 10.1016/j.dsx.2021.102235.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2021.102235</ArticleId><ArticleId IdType="pmc">PMC8317446</ArticleId><ArticleId IdType="pubmed">34384972</ArticleId></ArticleIdList></Reference><Reference><Citation>Heubner L., Petrick P.L., G&#xfc;ldner A., Bartels L., Ragaller M., Mirus M., Rand A., Tiebel O., Beyer-Westendorf J., R&#xf6;&#xdf;ler M., et al. Extreme obesity is a strong predictor for in-hospital mortality and the prevalence of long-COVID in severe COVID-19 patients with acute respiratory distress syndrome. Sci. Rep. 2022;12:18418. doi: 10.1038/s41598-022-22107-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-22107-1</ArticleId><ArticleId IdType="pmc">PMC9626466</ArticleId><ArticleId IdType="pubmed">36319681</ArticleId></ArticleIdList></Reference><Reference><Citation>Notarte K.I., de Oliveira M.H.S., Peligro P.J., Velasco J.V., Macaranas I., Ver A.T., Pangilinan F.C., Pastrana A., Goldrich N., Kavteladze D., et al. Age, Sex and Previous Comorbidities as Risk Factors Not Associated with SARS-CoV-2 Infection for Long COVID-19: A Systematic Review and Meta-Analysis. J. Clin. Med. 2022;11:7314. doi: 10.3390/jcm11247314.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11247314</ArticleId><ArticleId IdType="pmc">PMC9787827</ArticleId><ArticleId IdType="pubmed">36555931</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., McCorkell L., Vogel J.M., Topol E.J. Long COVID: Major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 2023 doi: 10.1038/s41579-022-00846-2. Online ahead of print .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Swank Z., Senussi Y., Manickas-Hill Z., Yu X.G., Li J.Z., Alter G., Walt D.R. Persistent circulating SARS-CoV-2 spike is associated with post-acute COVID-19 sequelae. Clin. Infect. Dis. 2022;2022:ciac722.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10169416</ArticleId><ArticleId IdType="pubmed">36052466</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>